Viz.ai Collects its Third Edison Award

Viz.ai’s Viz HCM, an artificial intelligence (AI) software solution designed to detect and triage patients with signs of hypertrophic cardiomyopathy (HCM), has earned the company its third consecutive Edison Award.

Viz.ai was recognized in the Health Medical & Biotech category and Cardiovascular Health Diagnostics and Monitoring subcategory. Named after American inventor Thomas Alva Edison, the Edison Awards honor excellence in new product and service development, marketing, design and innovation. The awards are widely recognized as one of the premier accolades that companies can receive in the name of innovation and business success.

“We are honored to win our third, prestigious Edison Award, reaffirming our mission-critical work to transform AI-driven healthcare,” Viz.ai Co-Founder/CEO Dr. Chris Mansi said. “HCM is an underdiagnosed condition that is the most commonly inherited cardiac disease, yet, unfortunately only 15% of these patients are diagnosed. The recognition of Viz HCM, which accelerates the patient identification and journey for this serious disease, validates our efforts to help clinicians to deliver faster and better care.”

Viz HCM uses artificial intelligence to analyze all 12-lead electrocardiograms (ECGs) from a health system to identify suspected HCM cases, notify cardiology care teams and increase the likelihood that patients get the right follow-up and diagnosis. The Viz HCM module, developed as part of a multi-year funding agreement between Viz.ai and Bristol Myers Squibb, gained U.S. Food and Drug Administration De Novo approval in August 2023, creating a new regulatory category for cardiovascular machine learning-based notification software. Recent data presented at the American College of Cardiology meeting demonstrated that Viz HCM successfully helped identify 574 HCM patients in a single major academic hospital (Cleveland Clinic) in a nine-month period, highlighting Viz HCM’s ability for more effective disease detection.¹

All nominations are reviewed by the Edison Awards’ Steering Committee and an executive judging body. The panel is composed of more than 2,000 senior business executives and academics from product development, design, engineering, science, marketing, and education, as well as past winners.

Viz.ai uses AI algorithms and machine learning to increase the speed of diagnosis and care across more than 1,700 U.S. and European hospitals and health systems. The AI-powered Viz.ai One is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies.

Established in 1987, the Edison Awards aim to recognize, honor, and foster innovations and innovators. Named after Thomas Alva Edison (1847-1931), the annual competition honors excellence in new product and service development, marketing, human-centered design, and innovation. Past award recipients include Jony Ive, Martha Stewart, Carmichael Roberts and companies leading in innovation including; Nest, now part of Google, AMD, Intel, Naqi, 3M and Cargill. In 2021, the Edison Awards introduced the inaugural Lewis Latimer Fellowship program designed to celebrate, connect and bring together a community of innovative Black thought leaders.

Reference
¹ Real-World Artificial Intelligence–Based Electrocardiographic Analysis to Diagnose Hypertrophic Cardiomyopathy. JACC: Clinical Electrophysiology. https://www.jacc.org/doi/10.1016/j.jacep.2025.02.024